The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 14, 2023

Filed:

Dec. 26, 2017
Applicant:

Hefei Institutes of Physical Science, Chinese Academy of Sciences, Anhui, CN;

Inventors:

Qingsong Liu, Anhui, CN;

Jing Liu, Anhui, CN;

Xiaofei Liang, Anhui, CN;

Beilei Wang, Anhui, CN;

Kailin Yu, Anhui, CN;

Zongru Jiang, Anhui, CN;

Cheng Chen, Anhui, CN;

Chen Hu, Anhui, CN;

Wenchao Wang, Anhui, CN;

Fengming Zou, Anhui, CN;

Qingwang Liu, Anhui, CN;

Feng Li, Anhui, CN;

Wenliang Wang, Anhui, CN;

Li Wang, Anhui, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/505 (2006.01); A61P 35/02 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); C07D 239/47 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 413/14 (2006.01);
U.S. Cl.
CPC ...
A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61P 35/02 (2018.01); C07D 239/47 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 413/14 (2013.01);
Abstract

The present invention relates to a kinase inhibitor, comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also relates to a pharmaceutical composition comprising the kinase inhibitor, and to uses and methods for using these compounds and compositions to inhibit the activity of wild-type FLT3, mutant FLT3-ITD, PDGFRα and/or PDGFRβ kinase in a cell or a subject, as well as uses and methods of these compounds and compositions to preventing or treating kinase-associated conditions in a subject.


Find Patent Forward Citations

Loading…